Jiabin Cai

Jiabin Cai

Auto-generated profile, based on publicly available information

Jiabin Cai

Department of Surgical Oncology, Children's Hospital Zhejiang University School of Medicine National Clinical Research Center for Children and Adolescents' Health and Diseases Hangzhou Zhejiang China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Cancer Research Communications
Verified
Journal Article
Open access
TTTing Tao
Ting Tao
JCJiabin Cai
Jiabin Cai
YTYinbing Tang
Yinbing Tang
DLDongfang Lu
Dongfang Lu
ZLZhang Lifeng
Zhang Lifeng
JWJinhu Wang
Jinhu Wang
Low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) is increasingly recognized for its utility in identifying somatic copy-number aberration (CNA). In this study, we analyzed LP-WGS ctDNA data from 73 pediatric patients with neuroblastic tumor and 11 healthy controls to explore diagnostic value of ctDNA CNA burden (including the genotypings) with a customized bioinformatics workflow. We found that a high baseline ctDNA CNA burden [tumor DNA fraction (TFx) ≥0.2%] was present in 36 of 41 patients (87.80%) with neuroblastoma, six of 22 patients (27.27%) with ganglioneuroblastoma, and three of 10 patients (30%) with ganglioneuroma. High baseline ctDNA CNA burden could predict high-risk neuroblastic tumors with an area under curve (AUC) of 0.95, sensitivity of 94.12%, and specificity of 100%. Frequent chromosomal copy-number changes, including chr17q gain, chr7 gain, chr3p loss, and chr11q loss, were found in ctDNA. Gain of chr17q demonstrated the highest diagnostic value with an AUC of 0.92, indicating strong sensitivity and specificity for detecting high-risk neuroblastic tumors. The homologous recombination deficiency score in the high- and intermediate-risk groups was significantly elevated compared with those in the low-/very low–risk group. The TFx levels and segmental alterations significantly decreased in patients with neuroblastic tumor who underwent chemotherapy, from median TFx = 13.82% before treatment to 0.24% after treatment (P < 0.0001). Our findings highlight the effectiveness of LP-WGS ctDNA CNA analysis as a promising approach for diagnosis and risk stratification of pediatric neuroblastic tumors and for monitoring chemotherapy response. Particularly, ctDNA analysis is minimally invasive, rapid, and cost-effective, which could bring additional benefits in pediatric practices. Significance: Our results support the development of ctDNA CNA analysis as a robust and minimally invasive approach for early detection, molecular diagnosis, and risk stratification of peripheral neuroblastic tumors.

12 January 2026 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
JCJiabin Cai
Jiabin Cai
MCMing Chen
Ming Chen
YHYuanqiao He
Yuanqiao He
MHMin He
Min He
JXJieni Xiong
Jieni Xiong
YTyongmin tang
yongmin tang

6 January 2026
Verified
Other
Open access
TTTing Tao
Ting Tao
JCJiabin Cai
Jiabin Cai
YTYinbing Tang
Yinbing Tang
DLDongfang Lu
Dongfang Lu
ZLZhang Lifeng
Zhang Lifeng
JWJinhu Wang
Jinhu Wang
CIN in plasma ctDNA predicts the high-risk group in patients with pNT. A, A Heatmap of segmental alterations in ctDNA from patients with pNT. Patient information is shown at the bottom of the panel. Scale bar represents copy-number Z-score of each segment. B, Representative genome-wide copy-number variation in a healthy child (top) and a patient with pNT (bottom). C, ROC curves illustrated the diagnostic performance of chromosomal aberrations in distinguishing between healthy controls and high-risk pNTs. AUC is shown for each chromosomal aberration. D, HRD score in different risk groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. **, P < 0.01; ****, P < 0.0001; ns, not significant. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.

6 January 2026
Verified
Other
Open access
TTTing Tao
Ting Tao
JCJiabin Cai
Jiabin Cai
YTYinbing Tang
Yinbing Tang
DLDongfang Lu
Dongfang Lu
ZLZhang Lifeng
Zhang Lifeng
JWJinhu Wang
Jinhu Wang
Statistical analysis of TFx between various clinicopathologic groups in pNTs.

6 January 2026
Verified
Other
Open access
TTTing Tao
Ting Tao
JCJiabin Cai
Jiabin Cai
YTYinbing Tang
Yinbing Tang
DLDongfang Lu
Dongfang Lu
ZLZhang Lifeng
Zhang Lifeng
JWJinhu Wang
Jinhu Wang
Low-pass whole-genome sequencing (LP-WGS) of circulating tumor DNA (ctDNA) is increasingly recognized for its utility in identifying somatic copy-number aberration (CNA). In this study, we analyzed LP-WGS ctDNA data from 73 pediatric patients with neuroblastic tumor and 11 healthy controls to explore diagnostic value of ctDNA CNA burden (including the genotypings) with a customized bioinformatics workflow. We found that a high baseline ctDNA CNA burden [tumor DNA fraction (TFx) ≥0.2%] was present in 36 of 41 patients (87.80%) with neuroblastoma, six of 22 patients (27.27%) with ganglioneuroblastoma, and three of 10 patients (30%) with ganglioneuroma. High baseline ctDNA CNA burden could predict high-risk neuroblastic tumors with an area under curve (AUC) of 0.95, sensitivity of 94.12%, and specificity of 100%. Frequent chromosomal copy-number changes, including chr17q gain, chr7 gain, chr3p loss, and chr11q loss, were found in ctDNA. Gain of chr17q demonstrated the highest diagnostic value with an AUC of 0.92, indicating strong sensitivity and specificity for detecting high-risk neuroblastic tumors. The homologous recombination deficiency score in the high- and intermediate-risk groups was significantly elevated compared with those in the low-/very low–risk group. The TFx levels and segmental alterations significantly decreased in patients with neuroblastic tumor who underwent chemotherapy, from median TFx = 13.82% before treatment to 0.24% after treatment (P < 0.0001). Our findings highlight the effectiveness of LP-WGS ctDNA CNA analysis as a promising approach for diagnosis and risk stratification of pediatric neuroblastic tumors and for monitoring chemotherapy response. Particularly, ctDNA analysis is minimally invasive, rapid, and cost-effective, which could bring additional benefits in pediatric practices.Significance:Our results support the development of ctDNA CNA analysis as a robust and minimally invasive approach for early detection, molecular diagnosis, and risk stratification of peripheral neuroblastic tumors.

6 January 2026
Verified
Other
Open access
TTTing Tao
Ting Tao
JCJiabin Cai
Jiabin Cai
YTYinbing Tang
Yinbing Tang
DLDongfang Lu
Dongfang Lu
ZLZhang Lifeng
Zhang Lifeng
JWJinhu Wang
Jinhu Wang
CNA burden in plasma ctDNA enables diagnosis and risk stratification of pNTs. A–E, TFx in various clinicopathologic groups of pNTs. Boxes indicate the median (horizontal line), 25th percentile, and 75th percentile; whiskers indicate distances from the largest and smallest value to each end of the box that are within 1.5 × box length. Values were compared with the Wilcoxon test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. F–H, ROC curves of the pNT-UCAD model for risk-based stratification analysis. The TFx cutoff was defined by maximizing the Youden index (sensitivity + specificity − 1) using the pROC R package. Amp, amplified; GN, ganglioneuroma; GNB, ganglioneuroblastoma; HC, healthy control; NB, neuroblastoma; non-amp, nonamplified.